Eur Rev Med Pharmacol Sci 2019; 23 (13): 5595-5602

DOI: 10.26355/eurrev_201907_18293

Oncogene miR-934 promotes ovarian cancer cell proliferation and inhibits cell apoptosis through targeting BRMS1L

Y. Hu, Q. Zhang, J. Cui, Z.-J. Liao, M. Jiao, Y.-B. Zhang, Y.-H. Guo, Y.-M. Gao

Department of Gynecological Oncology, Shaanxi Provincial Tumor Hospital, Xi’an, China. gyhture001@163.com


OBJECTIVE: Ovarian cancer is a common malignant cancer among women. Increasing studies have demonstrated that microRNAs function as important regulation factors in the progression of ovarian cancer.
MATERIALS AND METHODS: Human ovarian cancer cell lines HO8910 and OVCAR-3 were transfected with miR-934 inhibitor and corresponding negative control (inhibitor control). Cell proliferation and apoptosis were detected by cell counting kit-8 (CCK-8) and TUNEL assay, respectively. The expression levels of proliferation/apoptosis-related genes and BRMS1L were measured by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) and Western blotting. Furthermore, the association between miR-934 and BRMS1L was investigated through luciferase reporter assays.
RESULTS: MiR-934 was significantly increased in ovarian cancer cell lines, whereas BRMS1L was significantly decreased. Downregulated miR-934 remarkably inhibited cell proliferation and induced cell apoptosis. Meanwhile, miR-934 could influence the expression levels of Ki67, Cyclin D1, Caspase3, and Bcl-2. In addition, BRMS1L was identified as a target gene of miR-934.
CONCLUSIONS: Oncogene miR-934 promotes ovarian cancer cell proliferation and inhibits cell apoptosis through targeting BRMS1L. MiR-934 and BRMS1L may be novel biomarkers or therapeutic targets for ovarian cancer in the future.

Free PDF Download

To cite this article

Y. Hu, Q. Zhang, J. Cui, Z.-J. Liao, M. Jiao, Y.-B. Zhang, Y.-H. Guo, Y.-M. Gao
Oncogene miR-934 promotes ovarian cancer cell proliferation and inhibits cell apoptosis through targeting BRMS1L

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 13
Pages: 5595-5602
DOI: 10.26355/eurrev_201907_18293